DTC Scrutiny Accelerating in 2026: Mintz
FDA appears to be sustaining — and in some cases accelerating — its scrutiny of prescription drug advertising months after launching a high-profile enforcement push in 9/2025. The September initiative included 65 Warning and untitled letters issued the same day to biopharmaceutical manufacturers. In the months since, CDER Office of Prescription Drug Promotion (OPDP) has maintained pressure and issued 16 additional untitled letters, according to a Mintz legal update, representing a sharp uptick compared with the “few letters a year” that had become typical in recent years. In several cases, companies reportedly received advisory letters within weeks or even days of launching new promotional campaigns, suggesting a marked acceleration in review and enforcement timelines.
While direct-to-consumer (DTC) advertising has drawn particular attention, not all recent letters have focused on consumer-facing materials. Some have challenged promotional content directed at healthcare professionals, broadening the scope of scrutiny, the update notes
The stepped-up enforcement comes against a politically charged backdrop. HHS secretary Robert F. Kennedy Jr. has publicly criticized DTC pharmaceutical advertising and previously indicated a preference for banning it in the U.S. An outright prohibition, however, would likely face significant constitutional hurdles. Under First Amendment jurisprudence, commercial speech — including pharmaceutical advertising — is protected so long as it is truthful and not misleading.
Mintz legal experts say a categorical ban would face steep challenges in federal court. “A more feasible approach to the government restricting such commercial speech is to create unworkable regulatory requirements that result in so much uncertainty for manufacturers that they opt to limit their activities in the area rather than assume unknown risks,” the update says.
To date, regulators have not publicly escalated the letters being issued into administrative or judicial enforcement. But Mintz is predicting that 2026 could see a company openly challenge the agency’s conclusions in court or through public advocacy, particularly if disagreements arise over whether advertising claims are genuinely misleading or supported by adequate evidence.
For now, the FDA’s sustained enforcement tempo signals that prescription drug promotion — especially consumer-directed advertising — remains a top regulatory priority. Manufacturers launching new campaigns may need to prepare for closer and faster scrutiny than in years past, the update says.